

REMARKS

Claims 14-20 and 24-26 are pending. Reconsideration is requested.

Claims 14 and 24 stand rejected under U.S.C. § 112, first paragraph, because the specification, while being enabling for a compound having the formula aep PNA II as set forth in claim 14 wherein the compound is a peptide nucleic acid (PNA) and a pharmaceutical composition comprising the compound, allegedly does not reasonably provide enablement for the compound having the formula aep PNA II wherein the compound does not comprise a nucleobase (i.e., wherein the molecule is not a PNA).

Although Applicants do not agree, in order to advance prosecution, claim 14 has been amended to delete DNA intercalators and heterocyclic moieties. It is respectfully submitted that both claim 14 and claim 24 are free of the rejection. Reconsideration and withdrawal thereof are respectfully requested.

All objections and rejections having been addressed, it is respectfully submitted that this application is in condition for allowance, and Notice to that effect is respectfully requested.

Respectfully submitted,

Dated: 8/11/08



Ann S. Hobbs, Ph.D.
Registration No. 36,830
VENABLE
Post Office Box 34385
Washington, D.C. 20043-9998
Telephone: (202) 344-4800
Telefax: (202) 344-8300
ashobbs@venable.com